Asia Pacific Breast Cancer Screening Market to Grow at a CAGR of 5.4% to reach US$ 1,120.77 million from 2020 to 2027

The Asia Pacificbreast cancer screening market was valued at US$ 798.57 million in 2019 and is projected to reach US$ 1,120.77 million by 2027; it is expected to grow at a CAGR of 5.4% from 2020 to 2027.

As per the Centers for Disease Control and Prevention (CDC) definition, breast cancer screening refers tochecking a woman’s breasts for cancer before there are signs or symptoms of the disease. The purpose of screening tests is to discover cancer at an early stage when it can be operated or cured. At times, a screening test detects cancer when it is very small or growingslowly.

India Breast Cancer Screening Market Revenue and Forecast to 2027 (US$ Million)

Market Insights

Increasing Investmentsfor Research in Breast Cancer Management

Increasing research activities is likely to enhance the breast cancer screening market in Asia Pacific. For instance, “Novel combination of serum microRNA for detecting breast cancer in the early stage” was conducted in Japan. Furthermore, the government in Japan has initiated cancer control programs as it is one of the leading cause of death in Japan. Cancer screening programs are carried out throughout the country by the municipalities with the government support.

Additionally, increasing research for early diagnosis of breast cancer is likely to favor the breast cancer screening market in Australia. For instance, in October 2019, a NBCF funded (national breast cancer foundation) researcher Sydney University published theresults of pilot trial of 3D mammography (known as tomosynthesis), as per thestudy, breast cancer detection rates are higher with 3D mammography as compared withthe standard 2D mammography.

Test Type-Based Market Insights

Based on test type,the breast cancer screeningmarket is segmented into imaging test, Immunohistochemistry test, genetic test, and blood marker tests. In 2019,the imaging testsegment held the largest share of the market in 2019; moreoverit is anticipated to register the highest CAGR in the market during the forecast period.

Asia Pacific Breast Cancer Screening Market, by Test Type– 2019and 2027

End User-Based MarketInsights

Based onend user, the breast cancer screeningmarketis further segmented into hospitals, diagnostic centers, cancer institutes, and research laboratories. The hospitals segment held the largest share of the market in 2019; moreoverit is estimated to register the highest CAGR in the market during the forecast period.

Customize This Report To Suit Your Requirement

You will get customization on any report - free of charge - including parts of this report, or country-level analysis, Excel Data pack, as well as avail great offers and discounts for start-ups & universities

Get FREE CUSTOMIZATION

Asia Pacific Breast Cancer Screening Market: Strategic Insights

• Get Top Key Market Trends of this report.
  This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.

Free Sample PDF

Product launches and approvalsarethe commonly adopted strategies by companies to expand their footprint worldwide and meet the growing demand. The players operating in the breast cancer screeningmarketadopt the expansion, collaboration, and product launch strategies to enlarge customer base acrossthe world.These strategies allow the players to maintain their brand name globally. For instance, in October 2018, GE Healthcare launched a product, namely, the Invenia Automated Breast Ultrasound (ABUS) 2.0 in the US. The device is FDA-approved ultrasound supplemental breast screening technology, specifically designed for detecting cancer in dense breast tissue.

By Test Type

• Blood Marker Test
• Imaging Test
• Genetic Test
• Immunohistochemistry Test

By End User

• Diagnostic Centres
• Hospitals
• Research Laboratories
• Cancer Institutes

By Country

• China
• Japan
• India
• Australia
• South Korea

Company Profiles

• Koninklijke Philips N.V.
• Hologic, Inc.
• Becton, Dickinson and Company
• Myriad Genetics, Inc.
• Siemens Healthcare AG
• Exact Sciences Corporation
• OncoCyte Corporation
• POC Medical Systems
• DanaherCorporation
• General Electric Company

Report Scope

Asia Pacific Breast Cancer Screening Market Regional Insights

The regional trends and factors influencing the Asia Pacific Breast Cancer Screening Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses Asia Pacific Breast Cancer Screening Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.

Asia Pacific Breast Cancer Screening Market Report Scope

Asia Pacific Breast Cancer Screening Market Players Density: Understanding Its Impact on Business Dynamics

The Asia Pacific Breast Cancer Screening Market market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.

Major Companies operating in the Asia Pacific Breast Cancer Screening Market are:

1. Koninklijke Philips N.V.
2. Hologic, Inc.
3. Becton, Dickinson and Company
4. Myriad Genetics, Inc.
5. Siemens Healthcare AG

Disclaimer: The companies listed above are not ranked in any particular order.